****Sponsored by Interactive Offers, LLC.
The Company has assembled a world class team and is led by a CEO who has achieved more than $1B market caps on not one, but two previous companies!
In February of 2025, Aspire Biopharma, Inc. and PowerUp Acquisition Corp. successfully merged in a business combination to drive breakthrough innovations in FDA-approved drugs, nutraceuticals, and supplements
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
READ THE INVESTOR PRESENTATION HERE
________________________
Hello Everyone,
May has been an incredible month so far. We are going to talk a little more about that tomorrow but right now we want to focus on a brand new profile that we have never brought to your attention before.
This one has stabilized recently and is sitting at a price point right now that we feel could bring some attention to this one as we watch for a possible re-tracememt.
You will want to have ASBP on your screen this week.
Aspire Bio Labs (NASDAQ: ASBP) engages in the business of developing and marketing novel disruptive technology for the sublingual delivery of drugs and other products. Using Aspire’s patent-pending sublingual drug delivery mechanism, drugs:
Are Faster Acting– drugs and other products enter the bloodstream in a minute or two;
Bypass the Digestive Tract- far less of drugs and other products get digested and initial bypassing of the GI-tract can eliminate irritation and adverse reactions;
Are Used Efficiently by the Body: by avoiding a first-pass through the liver drugs avoid being metabolized; and
Are Easier to Take: a small amount of pleasant tasting powder or granules can be taken by those who have trouble with pills and capsules– even someone who is unconscious can be dosed with our products.
Aspire Bio Labs (NASDAQ: ASBP) has developed a novel formulation of sublingual aspirin that increases rapid absorption, eliminates the GI tract side effects, and by-passes first pass liver metabolism resulting in faster peak serum concentration and rapid inhibition of cyclooxygenase (Cox-1). This innovative technology could provide alternative choices in pain care and even help reduce the current opioid epidemic.
Key aspects include:
- Patented Delivery System specifically formulated to allow rapid sublingual absorption of aspirin into the blood stream and bypassing the gastrointestinal tract
- Fast absorption to help resolve heart attack and stroke
- Proprietary formula and manufacturing process
- Absorbed instantly in the mouth, which reduces adverse reactions in the stomach (GI tract), not requiring the taking of pills by those who struggle with swallowing.
- Large dosage escalation for back pain, arthritis pain, headache, post surgery and cancer pain.
Opportunity:
- Large Addressable Market: $80 billion combined analgesics and opioid market
- Prescription: Utilizing the FDA 505 (b)(2) Fast Track drug approval process.
- OTC: Once the Rx market has been thoroughly established, an opportunity will arise for an OTC product.
- First to market: Prescription strength version to be followed by OTC
- Proprietary Technology: Enables the ability to pursue broadened applications, using our solubility process, which can be used with other compounds such as supplements.
In February of 2025, Aspire Biopharma, Inc. and PowerUp Acquisition Corp. (Nasdaq: PWUP) successfully merged in a business combination to drive breakthrough innovations in FDA-approved drugs, nutraceuticals, and supplements.The new merged company is called Aspire Biopharma Holdings, Inc. and trades on Nasdaq under the symbol ASBP.
Highlights of the Merger:
- Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.
- Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel sublingual delivery mechanism to enhance the efficacy of FDA-approved drugs, nutraceuticals, and supplements.
- Innovative Drug Delivery Technology: Aspire’s patent-pending delivery system allows rapid sublingual absorption of drugs directly into the blood stream, thus on first pass, avoiding the gastrointestinal tract and liver, mitigating rapid metabolizing of drugs and easing tensions on body organs..
- Growth and Innovation: Anticipated proceeds from the transaction are expected to further fuel Aspire’s strategic growth plan to accelerate the development of its differentiated pipeline and finance several key therapeutic programs to data announcements.
A Sublingual Aspirin Product
ASBP’s Sublingual Aspirin Product addresses cardiology emergencies and pain management. It is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin, which has been developed by using the company’s patented formulation, and “trade secret” process.
Benefits of “rapid absorption” aspirin are: to stop heart attack and stroke; allow high dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.
In the planned initial launch of its sublingual products, Aspire has focused on the delivery of aspirin, which may be the most studied and accepted analgesic and anti-inflammatory.
Aspirin is over a century old and is traditionally available in several forms, including effervescence, powder, capsule, and tablet. Over 100 years of documented safety and efficacy data is readily available.
Aspirin is also the only drug in history to receive a certified recommendation by the FDA for heart attack, stroke and colon cancer prevention. However, current aspirin applications are limited due to side effects and the gastric tract.
The Company plans to seek FDA 505(b)(2) Fast Track designation for the prescription strength sublingual aspirin. The 505(b)(2) pathway specifically benefits new drugs that are similar to already approved drugs but have slight variations in formulation or administration routes. Aspire can reference the safety and efficacy data of the original innovator drugs–which are already FDA-approved–accelerating the approval process and reducing associated costs.
The Competitive Edge
ASBP’s sublingual aspirin product, which addresses cardiology emergencies and pain management among other impacts, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. Benefits of “rapid absorption” aspirin are to stop heart attack and stroke; allow high-dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.
Commercialization and Go-to-Market Strategy
- Launch the sublingual aspirin product initially in the Rx market, followed eventually by an OTC version, with the strategy of creating and preserving greater long-term value.
- Partner with an experienced end-to-end marketing and distribution firm. The company is currently evaluating potential partners.
- Significant Licensing Opportunity.
- Aspire is also developing important non-FDA products with limited regulatory hurdles to come to market sooner, such as a preworkout product and a melatonin-based sleep aid.
Manufacturing
ASBP has entered into a development and manufacturing agreement with a well-known manufacturer–Glatt, based in Ramsey, New Jersey–in the fourth quarter of 2024 to produce sufficient quantities of its sublingual drug product for the clinical trials required to obtain FDA approval to market the product and complete clinical trials.
Although the company believes that Glatt is capable of producing the drug product to support the company’s sublingual aspirin development plan, including its planned clinical trials, ASBP also believes there are a number of alternative third-party manufacturers that have similar capabilities and would be capable of providing sufficient quantities of drug product if necessary.
ASBP has entered into a fill-and-finish agreement with a contract manufacturer to convert sublingual aspirin manufactured by Glatt into packaged drug products that can be utilized in clinical trials and stability testing. The fill-and-finish contract manufacturer will package the aspirin product that has been produced by Glatt into a drug product to be used in the company’s upcoming clinical trials. The company believes that both Glatt and the fill-and-finish contract manufacturer are compliant under current good manufacturing practice, or cGMP, requirements and have experience with cGMP inspections of their respective facilities.
- Plans to use the sublingual aspirin manufactured by Glatt to conduct clinical trials to support approval of a section 505(b)(2) New Drug Application (“NDA”). An initial trial will be designed to study the pharmacokinetics of aspirin and its metabolites in blood following sublingual administration of a single dose of each of two different formulations of the Instaprin drug product and a single dose of standard oral aspirin. This initial trial is expected to enroll at least six healthy adult volunteers with each dose separated by a washout period of seven days and will provide information required to (i) select the optimal drug product formulation and (ii) inform the design of a second clinical trial to support FDA approval. The first trial will also demonstrate the relative quickness of Aspire’s sublingual aspirin’s absorption compared to orally administered aspirin tablets. The company plans to design a second clinical trial to demonstrate that sublingual administration of the final selected formulation delivers therapeutic concentrations of drug into the bloodstream, comparable to those of standard oral aspirin, but faster and without gastro-intestinal toxicity associated with oral aspirin. The second trials will also focus on the anti-platelet properties of the sublingual aspirin.
Commercialization
Subject to receiving marketing approvals, ASBP expects to commence commercialization activities by building a focused sales and marketing organization in the United States to sell its products, as well as the creation of a dedicated Medical Affairs team to support commercialization efforts. The company believes that such an organization will be able to address the physicians who are the key specialists in treating the patient populations for which its product candidates are being developed. Outside the United States, it expects to enter into distribution and other marketing arrangements with third parties for any of its product candidates that obtain marketing approval.
ASBP also plans to build a marketing and sales management organization to create and implement marketing strategies for any products that it markets through its own sales organization and to oversee and support its sales force.
Since the middle of the month we have seen interest come in to ASBP and the price stabilize over the past few sessions. Watch this one close for a bounce.
NEWS
May 20, 2025
Sidoti Events, LLC’s Virtual May Micro-Cap Conference
May 20, 2025
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
May 8, 2025
Apr 29, 2025
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
Apr 14, 2025
Apr 11, 2025
Apr 9, 2025
Mar 20, 2025
Mar 13, 2025
Mar 11, 2025
Mar 20, 2025
Mar 13, 2025
Mar 11, 2025
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
Mar 3, 2025
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
Feb 20, 2025
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
Feb 19, 2025
Sep 3, 2024
MANAGEMENT
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND SEVEN HUNDRED FIFTY USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY ASBP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.